

# Lyme Neuroborreliosis (LNB) – Clinical and Diagnostic Difficulties

## Lyme Neuroborrelioza (LNB) – trudności kliniczne i diagnostyczne

Dorota Dunin-Wąsowicz<sup>1</sup>, Beata Kasztelewicz<sup>2</sup>, Katarzyna Tomaszek<sup>1</sup>, Alicja Pawińska<sup>2</sup>, Janusz Książyk<sup>3</sup>, Anna Wieteska-Klimczak<sup>3</sup>, Elżbieta Jurkiewicz<sup>4</sup>, Katarzyna Dzierżanowska-Fangrat<sup>2</sup>

<sup>1</sup> Neurology and Epileptology Department The Children's Memorial Health Institute Warsaw, Poland

<sup>2</sup> Microbiology and Immunology Department The Children's Memorial Health Institute Warsaw, Poland

<sup>3</sup> Pediatric, Nutrition and Metabolic Diseases Department The Children's Memorial Health Institute Warsaw, Poland

<sup>4</sup> Department of Diagnostic Imaging The Children's Memorial Health Institute Warsaw, Poland

DOI:10.20966/chn.2017.53.406

### STRESZCZENIE

**Cel:** Zastosowanie metody RT-PCR dla wykrywania DNA *Borrelia burgdorferi* w płynie mózgowo-rdzeniowym u pacjentów pediatrycznych z różnymi objawami neurologicznymi i podejrzeniem choroby z Lyme. **Materiał i metody:** Badanie prospektywne przeprowadzono u 107 dzieci w wieku od 1–18 lat (średnio 12.2 lat). Badania serologiczne we krwi przeprowadzono dwuetapowo – test ELISA, a następnie test Western blot. W próbkach płynu mózgowo-rdzeniowego wykonywano test ELISA oraz badanie metodą RT-PCR celem potwierdzenia lub wykluczenia rozpoznania neuroborreliozy (LNB). U wszystkich pacjentów wykonywano badania neurologiczne, okulistyczne i neuroobrazowe. **Wyniki:** U 60 (56.1%) dzieci stwierdzono dodatnie wyniki przeciwciał IgG i/lub IgM w surowicy i/lub w płynie mózgowo-rdzeniowym. Tylko u 2/60 (3.3%) wykryto DNA *Borrelia burgdorferi* PMRDz oraz specyficzne przeciwciała w surowicy i w płynie mózgowo-rdzeniowym (przypadki LNB – aseptyczne zapalenie opon mózgowo-rdzeniowych z TIA oraz zapalenie nerwu II i nerwu VI). LNB zdiagnozowano u 33 pacjentów a u 22/107 (20.5%) rozpoznano choroby demielinizacyjne. U dzieci z LNB stwierdzono statystycznie znamienne wyższe miana IgG w PMRDz i wyniki testu Western blot – IgG p ( $\chi^2 > 9.333$ ) = 0.0023, WB- p ( $\chi^2 > 12.941$ ) = 0.0003. **Wnioski:** Wykrycie DNA *Borrelia burgdorferi* w PMRDz przy użyciu metody RT-PCR może być pomocne dla potwierdzenia diagnozy wczesnej LNB. Negatywne wyniki DNA *Borrelia burgdorferi* w PMRDz są szczególnie ważne dla wykluczenia LNB i przydatne dla ustalenia rozpoznania chorób demielinizacyjnych. Kuracja Ceftraxsonem podawanym dożylnie przez 4 tygodnie jest skuteczna w leczeniu neuroinfekcji, eliminacji DNA *Borrelia burgdorferi* z płynu mózgowo-rdzeniowego i poprawy klinicznej pacjentów.

**Słowa kluczowe:** neuroborrelioza, płyn mózgowo-rdzeniowy, metoda RT-PCR, choroby demielinizacyjne

### ABSTRACT

**Aim:** Assessment of clinical utility of *Borrelia burgdorferi* DNA detection in cerebrospinal fluid (CSF) and urine using RT-PCR method in pediatric patients with different neurological signs and symptoms and suspicion of Lyme disease. **Material and methods:** Prospective study was carried out in 107 children aged 1–18 (mean 12.2) years. Serological tests in blood were performed in two-step approach – ELISA followed by Western blot. ELISA test was performed on CSF samples as well as RT-PCR method for confirmation or exclusion of Lyme neuroborreliosis (LNB) diagnosis. All patients underwent neurological, ophthalmological and neuroimaging examinations. **Results:** In 60 (56.1%) children IgG and/or IgM *Borrelia* antibodies were positive in serum and/or CSF. Only in 2/60 (3.3%) *Borrelia burgdorferi* DNA was found in CSF with specific antibodies detected in serum and CSF – (LNB – aseptic meningitis with TIA and nerve II and VI neuritis cases). LNB was diagnosed in 33 patients and in 22/107 (20.5%) demyelinating diseases. IgG in CSF, Western blot test results were significantly higher in children with LNB – IgG p ( $\chi^2 > 9.333$ ) = 0.0023, WB- p ( $\chi^2 > 12.941$ ) = 0.0003. **Conclusions:** Detection of DNA *Borrelia burgdorferi* in CSF using RT-PCR method might be helpful for confirmation of early LNB diagnosis. Negative results for DNA *Borrelia burgdorferi* in CSF are especially important for exclusion of LNB and useful for establishment of demyelinating diseases diagnosis. Four-week intravenous Ceftriaxone course is sufficient for LNB neuroinfection treatment, elimination of DNA *Borrelia burgdorferi* from CSF and clinical improvement of patients.

**Key words:** neuroborreliosis, cerebrospinal fluid, RT-PCR method, demyelinating diseases

### INTRODUCTION

Tickborne spirochaetes of the *Borrelia burgdorferi sensu lato* genospecies cause Lyme disease. For many years Lyme neuroborreliosis (LNB) has been known as a frequent (14%–34% or 40%) manifestation of Lyme disease [1, 2]. Symptoms of LNB are not characteristic and typical for LNB only but may often mimic other neurological diseases. Diagnosis of LNB is based on clinical presentation of different neuro-

logical signs and symptoms supported by laboratory tests including cerebrospinal (CSF) examination. Serological tests are recommended for diagnosis of Lyme disease. IgM and IgG antibodies may be absent in some patients with early LNB. Positive or negative values of serological tests depend on assay performance and on prevalence of the disease in population. Therefore LNB diagnosis could be difficult. CSF examination is crucial for LNB diagnostic procedures.

However, direct methods (culture techniques and qualitative and quantitative PCR) are not available and recommended for routine LNB diagnosis [3–6].

**Aim:** Assessment of clinical utility of *Borrelia burgdorferi* DNA detection in CSF and urine using RT-PCR method in pediatric patients with suspicion of LNB.

## MATERIAL AND METHODS

Prospective study was carried out in 107 children (62–57.9% girls, 45–42.1% boys) aged 1–18 years (mean 12.2 years) between July 2013 and April 2017.

In all patients with different neurological signs and symptoms and suspicion of LNB, serology in blood, CSF and real-time PCR method in CSF and urine were performed. Serological tests in blood were performed in two-step approach involving screening test (*Borrelia* recombinant IgG/IgM ELISA, Biomedica) followed by Western blot (*Borrelia* NB IgM/IgG recomblot, Mikrogen Diagnostic) for reactive and equivocal serum samples (i.e.  $\geq 11$  BBU/ml). ELISA test was performed on CSF samples (samples suspected for LNB with values  $\geq 5$ BBU/ml).

Real-time PCR method was used for detection *Borrelia burgdorferi sensu lato* DNA in CSF and urine. Total bacterial DNA was extracted from clinical specimens (CSF or urine) using a commercial kit (QIAamp DNA mini Kit, Qiagen, Inc., Valencia, CA). The clinical samples were pre-processed as follows: 2 mL of urine or 1 ml of CSF sample was centrifuged (at 11 000 rpm for 20 min) to a final volume of 200  $\mu$ L (sample concentration). An internal standard (IS) was added directly into the concentrated sample at the beginning of the DNA extraction process. The extraction was done according to the manufacturer's specifications (blood and body fluid spin protocol) with the final elution volume of 50  $\mu$ L. Following DNA extraction real-time PCR was performed using GeneProof *Borrelia burgdorferi* PCR Kit (GeneProof, Czech Republic) on the 7500 real-time PCR System (Applied Biosystems) according to the manufacturer's protocol. Two controls: positive (*Borrelia burgdorferi* DNA) and negative (no template control) were included in each run. The 95% assay reproductivity cutoff was 0.532 copies/ $\mu$ L. Assay specificity includes genospecies: *B. burgdorferi sensu stricto*, *B. andersoni*, *B. bissetti*, *B. garini*, *B. afzeli*, *B. valaisiana*, *B. lusitanae*, *B. japonica*, *B. tanukii*, *B. turdi*, *B. sinica*.

All patients underwent neurological, ophthalmological examination and brain and/or spinal cord magnetic resonance imaging (MRI). The study protocol was approved by local Bioethics Committee.

## STATISTICAL ANALYSIS

STATISTICA 10 (t-Student test for continuous,  $\chi^2$  test for non-continuous variables, and p value of  $<0.05$  was considered as statistically significant).

## RESULTS

### 1. Exclusion of Lyme disease and other clinical diagnostic results

In 47 (43.9%) children specific serological tests in blood, CSF and *Borrelia burgdorferi sensu lato* DNA in CSF and urine were negative. In these patients, Lyme disease LNB was excluded. Demyelinating diseases diagnosis can be definitely established in 15 out of 47 children. Other 32 out of 47 patients had bacterial meningitis, sepsis, HSV -1 and HCMV neuroinfection, myelitis, Mellkerson-Rosenenthal, Miller-Fisher syndromes, headaches, ataxia caused by neuroblastoma, polyneuritis of the cranial nerves (nerves III, VI, VII), ADEM, cerebrovascular malformations.

### 2. Serological and RT-PCR results

In 60 (56.1%) children with clinically suspected neuroborreliosis, IgG and/or IgM *Borrelia* specific antibodies were positive in serum and/or CSF (by ELISA and Western blot tests). In 45 out of 60 patients (75%), *Borrelia* specific antibodies were positive in serum only. In 38 (63.4%) patients, IgM *Borrelia* specific antibodies were diagnosed in serum and CSF. Only in 2/60 (3.3%) *Borrelia burgdorferi sensu lato* DNA using RT-PCR method was found in CSF (10 days after the onset of symptoms) and also specific antibodies were detected in serum and CSF (tab. I). RT-PCR results for *Borrelia sensu lato* in urine were negative in all 107 patients (patient's urine was investigated during the same hospitalization as examination of the serum and CSF).

### 3. Patients with positive RT-PCR borrelial DNA results in CSF

In one 15 year old male (patient No1) with positive RT-PCR result (borrelial DNA  $>0.532$  copies/ $\mu$ L) in CSF only serum IgG antibodies ( $43 \geq 11$  BBU/ml) but no serum IgM were found. In this adolescent antibodies values -IgG ( $51 \geq 5$ BBU/ml) and IgM ( $7 \geq 5$ BBU/ml) were higher in CSF

**Table I.** Positive serological and RT-PCR results for *Borrelia burgdorferi* in 60/107 (56.1%) patients

**Tabela I.** Dodatnie wyniki serologiczne i RT-PCR dla *Borrelia burgdorferi* u 60/107 (56.1%) pacjentów

	Serum only	Serum+CSF	Serum+CSF+ DNA <i>Borrelia</i> CSF(+)	Total
IgG only	7	4	1*	12 (20%)
IgM only	34	4	0	38 (63.4%)
IgG+IgM	4	5	1**	10 (16.6%)
Total	45 (75%)	13 (21.7%)	2 (3.3%)	60 (100%)

1\* (serum IgG+, IgM-), CSF (IgG+, IgM+)

1\* (surowica IgG+, IgM-), PMRDz (IgG+, IgM+)

1\*\* (serum IgG+, IgM+), CSF (IgG+, IgM+)

1\*\* (surowica IgG+, IgM+), PMRDz (IgG+, IgM+)

than in serum. Antibody index (AI) IgG value was 1.18. CSF analysis in patient No1 revealed elevated pleocytosis (63 cell/ $\mu$ L), protein level (102 mg/dL) and low glucose concentration (16 mg/dL). Patient No1 suffered from severe headache with paraesthesia and dysaesthesia in upper right limb with motoric and sensoric aphasia symptoms for one hour and additionally transient, few minute vision disturbances, also somnolence and vomiting. Diagnosis of LNB (aseptic meningitis with transient ischemic attack-TIA) was established (tab. II).

In a 7-year-old boy (patient No2) with *Borrelia burgdorferi sensu lato*, DNA detected in CSF both IgG and IgM antibodies were found in serum and in CSF. In patient No 2 specific antibodies values in serum were as follows: IgG  $23 \geq 11$  BBU/ml, IgM  $24 > 11$  BBU/ml and in CSF :IgG  $32 > 5$  BBU/ml, IgM  $12 \geq 5$  BBU/ml. AI IgG value was 1.39, and AI IgM-0.5. In patient No2, cerebrospinal analysis was normal (pleocytosis 2 cell/dL, protein level 24mg/dL) and he demonstrated right ocular strabismus and vision disturbances. In patient No2 diagnosis of LNB with nerve II and VI neuritis was established.

**Table II. Clinical and microbiological characteristic of 33 patients with LNB (group A) (part 1 and 2)**


**Tabela II. Charakterystyka kliniczna i mikrobiologiczna 33 pacjentów z LNB ( grupa A) (część 1 i 2)**

	Serum only IgG	Serum only IgM	Serum only IgG and IgM	Serum and CSF IgG	Serum and CSF IgM	Serum and CSF IgG and IgM	Serum IgG and CSF IgG and DNA <i>Borrelia</i> in CSF	Serum IgM and CSF IgM and DNA <i>Borrelia</i> in CSF	Serum IgG IgM and CSF IgG IgM and DNA <i>Borrelia</i> in CSF	Total (% of LNB)
Aseptic meningitis with myelitis	0	0	0	1	0	0	0	0	0	1 (3.03%)
Aseptic meningitis with cerebellitis	0	1	0	0	0	0	0	0	0	1 (3.03%)
Aseptic meningitis with nerve VII peripheral palsy(PFNP)	0	0	0	0	0	1	0	0	0	1 (3.03%)
<b>Aseptic meningitis with TIA (Patient No1)</b>	0	0	0	0	0	0	0	0	<b>1*(serum IgG+, IgM-)</b>	<b>1 (3.03%)</b>
Encephalitis	0	1	0	0	0	0	0	0	0	1 (3.03%)
Encephalitis with nerve II neuritis	0	1	0	0	0	0	0	0	0	1 (3.03%)
ADEM	0	0	0	1	1	0	0	0	0	2 (6.06%)
<b>Total</b>	<b>0</b>	<b>3</b>	<b>0</b>	<b>2</b>	<b>1</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>8 (24.2%)</b>
Neuritis -nerve II	1	0	0	0	0	0	0	0	0	1 (3.03%)
Neuritis -nerve II and VII	0	1	0	0	0	0	0	0	0	1 (3.03%)
<b>Neuritis -nerve II and VI (Patient No 2)</b>	0	0	0	0	0	0	0	0	<b>1</b>	<b>1 (3.03%)</b>
Nerve VII peripheral palsy (PFNP)	3	3	0	0	1	2	0	0	0	9 (27.3%)
GBS syndrome	0	2	0	0	0	0	0	0	0	2 (6.06%)
Stroke	0	0	0	1	0	0	0	0	0	1 (3.03%)
Neuritis -peripheral nerves	1	1	0	0	0	0	0	0	0	2 (6.05%)
Banwarth's syndrome	0	0	1	0	0	0	0	0	0	1 (3.03%)
Headaches with dizziness and vomits	2	2	1	0	1	0	0	0	0	6 (18.2%)
Concentration and memory disturbances	0	0	0	0	0	1	0	0	0	1 (3.03%)
<b>Total</b>	<b>7</b>	<b>9</b>	<b>2</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>25 (75.8%)</b>

Brain MRI revealed twisted intraocular nerves containing fluid in the nerves sheath (Figure 1).

Patient No 2 had many (>10) tick bites spirochaetes without erythema migrans, but patient No1 had none.

Control RT-PCR results for *Borrelia* DNA in CSF were negative after 4-week treatment with intravenous Ceftriaxone. Urine from patient No1 and No2 was investigated also after antibiotics therapy and the results were negative too.



**Figure 1.** Brain MRI (Patient No 2). (T1 – coronal view) – twisted intraocular nerves containing fluid in the nerves sheath

**Ryc. 1.** MRI mózgu ( Pacjent Nr 2). (T1– przekrój wieńcowy – kręte nerwy wzrokowe z płynem w osłonkach nerwów)

#### 4. Patients' clinical and microbiological treatment results

Table II presents characteristic of 33 out of 60 patients (group A) with LNB diagnosis based on clinical, neuroimaging and serological and RT-PCR method results. Peripheral nerve VII palsy (PFNP) in 9 (27.3%) and headaches

with dizziness and vomits in 6(18.2%) were found the most frequently in children with LNB. Aseptic meningitis, encephalitis and ADEM were diagnosed in 8 (24.2%) patients with LNB. Patient with aseptic meningitis and right nerve VII peripheral palsy had the highest values of IgG AI (2.03) and also IgM AI (2.3). Twenty three patients (23/33–69.7%) from group A with LNB were treated with intravenous Ceftriaxone course for 21–28 days and 10/33 (30.3%) also with additional 2 week oral antibiotics therapy.

Twenty seven (27) out of 60 patients (group B) had positive serological results for borrelial antibodies (1 serum IgG only, 23 serum IgM and 3 serum IgG and IgM). In all 27 children antibodies were negative in CSF and CSF pleocytosis was normal. Nineteen (19/27) children suffered from headaches without vomiting and dizziness caused by borreliosis. Eight (8/27–29.6%) patients with headaches were treated with 14–21 days intravenous Ceftriaxone course and 5/27–18.5% also with oral antibiotics for 2 weeks.

One-year-old male from group B had finally established mitochondrial disease diagnosis.

#### 5. Statistical results

Western blot results were statistically, significantly higher in group A with LNB than in group B without LNB – p ( $\chi^2 > 12.941$ ) = 0.0003 as well as IgG antibodies in CSF – p ( $\chi^2 > 9.333$ ) = 0.0023 but no IgM antibodies in CSF – p ( $\chi^2 > 1.492$ ) = 0.2219.

Between group A and B there were no statistically significant differences in CSF analysis results of pleocytosis and protein (table III). Pleocytosis in CSF – p ( $\chi^2 > 3.506$ ) = 0.061, protein in CSF – p ( $\chi^2 > 0.21$ ) = 0.650.

#### 6. Other results

Only in one patient No1 with LNB oligoclonal bands were detected in CSF. Also in all 22 out of 107 (20.6%) patients with demyelinating diseases oligoclonal bands were found in CSF.

Fifteen (15/107–14%) patients had tick-bites including only 3/33(9%) patients from group A with LNB. One fe-

**Table III.** Comparison of CSF analysis results (pleocytosis and protein level) in group A (LNB) and group B (without LNB)

**Tabela III.** Porównanie wyników badań PMRDz (peocytoza i stężenie białka) w grupie A ( LNB) I grupie B (bez LNB)

CSF analysis	Normal pleocytosis (1-12/ $\mu$ L mean 3/ $\mu$ L)	Elevated pleocytosis (63-503/ $\mu$ L mean 138/ $\mu$ L)	Normal protein level (20-40mg/dL)	Elevated protein level (50-161mg/dL, mean 78mg/dL)	Total
Number of patients – Group A (LNB)	29 (87.9%)	4*(12.1%)	28 (84.9%)	5**(15.1%)	33 (100%)
Number of patients Group B (without LNB)	27 (100%)	0 (0%)	24 (88.9%)	3 (11.1%)	27 (100%)

\*Maximum pleocytosis value 503 cells/ $\mu$ L (467 mononuclear cells/ $\mu$ L)

\*Maksymalna wartość pleocytozy 503 komórek/ $\mu$ L (467 monocytów/ $\mu$ L)

\*\* Maximum protein level 161mg/dL

\*\* Maksymalne stężenie białka 161mg/dL

No statistically significant differences: pleocytosis in CSF- p ( $\chi^2 > 3.506$ ) = 0.061, protein in CSF - p ( $\chi^2 > 0.21$ ) = 0.650

Brak różnic istotnych statystycznie: peocytoza w PMRDz- p ( $\chi^2 > 3.506$ ) = 0.061, białko w PMRDz- p ( $\chi^2 > 0.21$ ) = 0.650

male adolescent had more than 30 tick-bites and suffered from headaches but no LNB. A few months before diagnostic procedures only one (1/107–0.9%) patient with headaches without LNB had erythema migrans. Tick-borne encephalitis was diagnosed in one (1/107–0.9%) 5-year-old female with only positive serum IgM borrelial antibodies.

### 7. Patients with demyelinating diseases diagnosis

Demyelinating diseases diagnosis was finally established in 22 out of 107 (25.2%) patients. In 15 specific serological tests in blood, CSF and *Borrelia burgdorferi sensu lato* DNA in CSF and urine were negative – 13 patients had multiple sclerosis, 1 neuromyelitis optica-NMO and 1 Balo concentric sclerosis. Multiple sclerosis diagnosis was also established in 7 out of 27 patients from group B with positive serological results for borrelial antibodies.

## DISCUSSION

In patients with neuroborreliosis different form of *Borrelia burgdorferi sensu lato* were found in neurons and astrocytes [7]. CNS involvement is possible at any stage of Lyme disease and even in patients with erythema migrans [8]. Therefore CSF analysis is crucial for LNB clinical diagnosis. In some patients specific antibodies in serum may occur later than in CSF. At the time of diagnosis in 17% of patients anti-Borrelia antibodies were found in CSF but not in serum [9]. Diagnosis of early and late LNB based on serological tests and immune response as well differentiation diagnosis with other neurological diseases is sometimes difficult [6–10].

For detection of *Borrelia burgdorferi sensu lato* DNA in body fluid samples (e.g. synovial fluid, blood and also CSF) many PCR-based methods protocols have been developed since 1989 [11–13]. However, in pediatric and adult population, the data concerning borrelial DNA investigation in CSF by different PCR methods are not frequent [14–27]. Sensitivity of the PCR methods for CSF diagnosis in early LNB is relatively low (10–30%), but could be even lower in late LNB, because spirochaetes can migrate to the different central nervous system tissues [28, 29].

In investigated group only in two patients in early stage of the disease DNA *Borrelia burgdorferi* was found in CSF using PCR method, also with specific antibodies in CSF and serum. This is additional confirmation of early LNB diagnosis. Patient No1 suffered from aseptic meningitis but also brain vessels involvement with clinical signs and symptoms of TIA. Stroke diagnosed in one patient from investigated group with IgG specific antibodies in CSF and serum was also reported as a sequent of inflammation process caused by spirochaetes *Borrelia* and even first presentation of Lyme disease [30, 31].

Central nerves involvement, especially nerve VII, is typical for LNB. Patient No 2 had severe optic nerve neuritis, documented in brain MRI. Different ophthalmological manifestation of LNB is also known [32].

Negative control CSF examination using RT-PCR method, as well as complete recovery after four week intravenous Ceftriaxone treatment in patients No1 and No 2, gives a strong evidence that according to the Euro-

pean Federation of Neurological Societies (EFNS) guidelines [28] this LNB therapy (14–28 days iv Ceftriaxone) is sufficient.

Peripheral nerve VII palsy (PFNP) was the most frequent clinical sign in patients with LNB, but only one child suffered from aseptic meningitis and peripheral nerve VII palsy. Combination of aseptic meningitis with PFNP was reported more frequently – in 17% of children [33]. Other cranial nerves involvement was also described as an uncommon manifestation of neuroborreliosis in children [34].

We had diagnosed typical for LNB aseptic meningitis with myelitis and aseptic meningitis with cerebellitis with IgG anti-Borrelia antibodies in CSF and serum and also cases of encephalitis.

Rocha et al. [35] reported a child neuroborreliosis presenting as ADEM and confirmed by PCR method in CSF. However, in our two patients with ADEM diagnosis and LNB DNA *Borrelia* was not found in CSF, but IgG, IgM antibodies were detected in CSF and serum. We diagnosed two patients with Guillain-Barré syndrome (GBS) and *Borrelia* infection had been found in GBS [36]. Banwarth's syndrome, peripheral nerves neuritis and concentration and memory disturbances were rarely observed in investigated group. Headaches with dizziness and vomits were frequent in patients with LNB (table II). Less severe headaches were typically observed in investigated patients with borreliosis, but without LNB.

According to the data from literature [3], erythema migrans and tick-bites were also very rare in the study population.

Significantly higher Western blot results in group A with LNB than in group B without LNB and also significantly higher IgG in CSF indicates more intensive and longer inflammation process.

It is well-known that neurological manifestation of Lyme disease and neuroimaging examination results can imitate multiple sclerosis but treatment options and also prognosis are completely different [37, 38]. Therefore fast differential diagnosis of multiple sclerosis and neuroborreliosis is especially important. In investigated group multiple sclerosis and other demyelinating diseases were diagnosed frequently, not only in patients with totally negative serological and RT-PCR results, but also in patients with positive serology but negative DNA *Borrelia burgdorferii* in CSF. In these clinical situations negative result RT-PCR method for borrelial DNA in CSF was especially useful for differentiation between both diseases.

In all investigated children, DNA *Borrelia burgdorferi* using RT-PCR methods were negative in urine. Therefore, according to our data this diagnostic test does not seem to be useful.

Nowadays, laboratory and also clinical diagnosis of Lyme disease and neuroborreliosis still have many traps and challenges [39, 40] and need further investigations.

## CONCLUSIONS

1. Detection of DNA *Borrelia burgdorferi* in CSF using RT-PCR method might be helpful for confirmation of early LNB diagnosis.
2. Negative results for DNA *Borrelia burgdorferi* in CSF are especially im-

portant for exclusion of LNB and useful for establishment of demyelinating diseases diagnosis.

3. Four-week intravenous Ceftriaxone course is sufficient for LNB neuroinfection treatment, elimination of DNA *Borrelia burgdorferi* from CSF and clinical improvement of patients.

## REFERENCES

- [1] Cimmino M.A.: Relative frequency of Lyme borreliosis and of its clinical manifestation in Europe. European Community Concerted Action on Risk Assessment in Lyme borreliosis. *Infection* 1998; 26: 298–300.
- [2] Younger D.S.: Epidemiology of Lyme Neuroborreliosis. *Neurol Clin* 2016; 34: 875–886.
- [3] Ornstein K.J., Berglund J., Nilsson I., et al.: Characterization of Lyme borreliosis isolates from patients with erythema migrans and neuroborreliosis in southern Sweden. *J Clin Microbiol* 2001; 39: 1294–1298.
- [4] Ornstein K.J., Berglund J., Bergstrom S. et al.: Three major Lyme Borrelia genospecies (*Borrelia burgdorferi sensu stricto*, *B. afzelii* and *B. garinii*) identified in cerebrospinal fluid from patients with neuroborreliosis in Sweden. *Scand J Infect Dis* 2002; 34: 341–346.
- [5] Hansen K, Lebech A.M.: The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985–1990. A prospective study of 187 patients with *Borrelia burgdorferi* specific intrathecal antibody production. *Brain*. 1992; 115(Pt 2):399–423 .
- [6] Schwenkenbecher P, Pul R., Wurster U. et al.: Common and uncommon neurological manifestation of neuroborreliosis leading to hospitalization. *BMC Infect Dis* 2017; 17: 90
- [7] Miklossy I., Kasas S., Zurn A.D., et al.: Persisting atypical cystic forms of *Borrelia burgdorferi* and local inflammation in Lyme neuroborreliosis. *J Neuroinflamm* 2008; 5: 1–18.
- [8] Coyle P.K, Schutzer S.E. :Neurologic aspects of Lyme disease. *Med Clin North Am*. 2002; 86: 261–284.
- [9] Henningsson A.J., Malmavall B.E., Ernerudh A., et al.: Neuroborreliosis an epidemiological, clinical and healthcare cost study from endemic area in the south-east of Sweden. *Clin Microbiol Infect* 2010; 16: 1245–1251.
- [10] Sjowall J., Carlsson A., Vaarala O., et al.: Innate immune responses in Lyme Borreliosis: enhanced tumor necrosis factor- $\alpha$  and interleukin-12 in asymptomatic individuals in response to live spirochetes. *Clin Exp Immunol* 2005; 141: 89–98.
- [11] Schmidt B.L.: PCR in laboratory diagnosis of *Borrelia burgdorferi* infections. *Clin Microbiol Rev* 1997; 10: 185–201.
- [12] Schwaiger M., Peter O., Cassinotti P.: Routine diagnosis of *Borrelia burgdorferi* (sensu lato) infections using a real-time PCR assay. *Clin Microbiol Infect* 2001; 7: 461–469.
- [13] Aguero-Rosenfeld M.E., Wang G., Schwartz I., et al.: Diagnosis of Lyme Borreliosis. *Clin Microbiol Rev* 2005; 18: 484–509.
- [14] Lebach A.M.: Polymerase chain reactions in diagnosis of *Borrelia burgdorferi* infections and studies on taxonomic classification. *APMIS Suppl* 2002; 105: 1–40.
- [15] Ruzic-Sabljić E., Lotric-Furlan S., Maraspin V., et al.: Analysis of *Borrelia burgdorferi sensu lato* isolated from cerebrospinal fluid. *APMIS* 2001; 109: 707–713.
- [16] Oksi J.M., Mariamaki M., Nikoskelainen J., et al.: *Borrelia burgdorferi* detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. *Ann Med* 1999; 31: 225–232.
- [17] Priem S., Rittig M.G., Kamradt T., et al.: An optimized PCR leads to rapid and highly sensitive detection of *Borrelia burgdorferi* in patients with Lyme borreliosis. *J Clin Microbiol* 1997; 35: 685–690.
- [18] Zbinden R., Goldenberger D., Lucchini G.M., et al.: Comparison of two methods for detecting intrathecal synthesis of *Borrelia burgdorferi* specific antibodies and PCR for diagnosis of Lyme neuroborreliosis. *J Clin Microbiol* 1994; 32: 1795–1798.
- [19] Huppertz H.I., Schmidt H., Karch H.: Detection of *Borrelia burgdorferi* by nested Polymerase chain reaction in cerebrospinal fluid and urine in children with neuroborreliosis. *Eur J Pediatr* 1993; 152: 414–417.
- [20] Debiec M., Gautier P., Hackel C., et al.: Detection of *Borrelia burgdorferi* in biological samples using the polymerase chain reaction assay. *Res Microbiol* 1991; 142: 565–572.
- [21] Christen H., Eiffert H., Ohlenbusch A., et al.: Evaluation of the polymerase chain reaction for the detection of *Borrelia burgdorferi* in cerebrospinal fluid of children with peripheral facial palsy. *Eur J Pediatr* 1995; 154: 374–377.
- [22] Nocton J., Dressler F., Rutledge B.J., et al.: Detection of *Borrelia burgdorferi* DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. *J Infect Dis* 1996; 174: 623–627.
- [23] Amouriaux P., Assous M., Margarrita B., et al.: Polymerase chain reaction with the 30-kb circular plasmid of *Borrelia burgdorferi* B 31 as a target for detection of the Lyme borreliosis agents in cerebrospinal fluid. *Res Microbiol* 1993; 144: 211–219.
- [24] Liebling M., Nishio M.J., Rodriguez A., et al.: The polymerase chain reaction for the detection of *Borrelia burgdorferi* in human body fluids. *Arthritis Rheum* 1993; 36: 665–675.
- [25] Jaulhac B., Nicolini P., Piemont Y., et al.: Detection of *Borrelia burgdorferi* in cerebrospinal fluid of patients with Lyme Borreliosis. *N Engl J Med* 1993; 324: 1440.
- [26] Luft B., Steinman C.R., Neimark H.C., et al.: Invasion of the central nervous system by *Borrelia burgdorferi* in acute disseminated infection. *JAMA* 1992; 267:1364–1367.(Erratum,268:872).
- [27] Keller T., Halperin J.J., Whitman M., et al.: PCR detection of *Borrelia burgdorferi* DNA in cerebrospinal fluid of Lyme neuroborreliosis patients. *Neurology* 1992; 42: 32–42.
- [28] Mygland A., Ljostad U., Fingerele V., et al.: European Federation of Neurological Societies.: EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. *Eur J Neurol*. 2010; 17: 8–16.
- [29] Coyle P.K, Schutzer S.E. :Neurologic aspects of Lyme disease. *Med Clin North Am*. 2002; 86: 261–284.
- [30] Almoussa M., Groertzen A., Fanser B., et al.: Stroke as an unusual first presentation of Lyme disease. *Case Rep Neurol Med* 2015; 389081–389084.
- [31] Wittwer B., Pelletier S., Ducrocq X., et al.: Cerebrovascular events in Lyme neuroborreliosis. *J Stroke Cerebrovasc Dis* 2015; 24: 1671–1678.
- [32] Lesser R.L., Kormehl E.W., Pachner A.R.: Neuroophthalmologic manifestation of Lyme disease. *Ophthalmology* 1990; 97: 699–706.
- [33] Waespe N., Steffen I., Heining U.: Etiology of aseptic meningitis, peripheral facial nerve palsy, and a combination of both in children. *Pediatr Infect Dis* 2010; 29: 453–456.
- [34] Baumann M., Brinbacher R., Koch J., et al.: Uncommon manifestations of neuroborreliosis in children. *Eur J Paediatr Neurol* 2010; 14: 274–277.
- [35] Rocha R., Lisboa L., Neves J., et al.: Neuroborreliosis presenting as acute disseminated encephalomyelitis. *Pediatr Emerg Care* 2012; 28: 1374–1376.
- [36] Horneff G., Huppertz H.I., Muller K., et al.: Demonstration of *Borrelia burgdorferi* infection in a child with Guillain-Barré syndrome. *Eur J Paediatr* 1993;52: 810–812.
- [37] Radolović Prenc L., Telarovic S., Vidovic J., et al.: Neuroborreliosis: diagnostic problem in distinguishing from multiple sclerosis. *Neurol. Croat*. 2014; 63: 1–2.
- [38] Schmutzhard E.: Multiple sclerosis and Lyme borreliosis. *Wien Klin Wochenschr* 2002; 114: 539–543.
- [39] Marques A.: Laboratory diagnosis of Lyme disease – advances and challenges. *Infect Dis Clin North Am*. 2015; 29: 295–307.
- [40] Ljostad U., Mygland A. :Chronic Lyme; diagnostic and therapeutic challenges. *Acta Neurol Scand Suppl*. 2013; 196: 38–47.

## Correspondence:

Dr hab.n.med Dorota Dunin-Wąsowicz, Klinika Neurologii i Epileptologii Instytut – “Pomnik-Centrum Zdrowia Dziecka”, Aleja Dzieci Polskich 20 email: ddwasowicz@gmail.com

Praca zrealizowana w ramach grantu S 130/2013 finansowanego ze środków MNiSW w latach 2012–2016.